NEW YORK, February 14, 2017 /PRNewswire/ --
Today's attention is directed to the Drug Manufacturers industry whichis involved in the manufacturing and processing of pharmaceutical products. The profitability of individual companies in this space depends on their ability to discover and market new drugs. This morning, Stock-Callers.com presents these four equities
Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd's shares jumped 5.62%, closing Monday's trading session at $34.00. The stock recorded a trading volume of 22.84 million shares, which was above its three months average volume of 10.50 million shares. Shares of the Company have advanced 0.18% in the last month. The stock is trading 3.41% below its 50-day moving average. Additionally, shares of Teva Pharma, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have a Relative Strength Index (RSI) of 49.07.
On February 13th, 2017, Teva reported that Q4 2016 revenues of $6.5 billion, up 33% on a y-o-y basis. The Company's GAAP gross profit was $3.4 billion in Q4 2016, up 19% compared to Q4 2015. GAAP gross profit margin was 52.2% in Q4 2016, compared to 58.3% in Q4 2015. Teva's GAAP net loss attributable to ordinary shareholders and GAAP diluted EPS were $1.0 billion and a loss of $1.10, respectively, in Q4 2016, compared to income of $500 million and EPS of $0.55 in Q4 2015.
On February 13th, 2017, research firm Maxim Group reiterated its 'Hold' rating on the Company's stock with a decrease of the target price from $41 a share to $40 a share. Visit us today and download your complete report on TEVA for free at:
On Monday, shares in Dublin, Ireland headquartered Endo International PLC recorded a trading volume of 4.15 million shares. The stock rose 0.33%, ending the day at $12.10. The Company's shares are trading below their 50-day moving average by 16.37%. Furthermore, shares of Endo International, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have an RSI of 36.23.
On January 31st, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $25 a share to $15 a share.
On February 13th, 2017, Endo International announced that it will report its Q4 and full-year 2016 financial results and provide an update on its ongoing corporate strategic review on February 28th, 2017. Members of its senior management team will host a conference call and webcast before the US financial markets open at 8:30 a.m. ET on the same day. The complimentary research report on ENDP can be accessed at:
Carlsbad, California headquartered Ionis Pharmaceuticals Inc.'s stock finished the day 1.48% higher at $46.09, with a total trading volume of 775,896 shares. The Company's shares have gained 12.55% in the previous three months. The stock is trading above its 200-day moving average by 30.93%. Additionally, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 52.19.
On February 02nd, 2017, Ionis Pharmaceuticals announced that it has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. Ionis and Biogen have a broad strategic collaboration to develop drugs to treat patients with neurological disorders. For this newest target, Ionis will continue to evaluate the target with the goal of advancing this program into development. Register for free on Stock-Callers.com and download the PDF research report on IONS at:
Shares in Dublin, Ireland-based Amarin Corp. PLC ended yesterday's session 2.35% lower at $3.32. The stock recorded a trading volume of 1.86 million shares, which was above its three months average volume of 1.67 million shares. The Company's shares have advanced 11.04% in the last one month, 7.79% over the previous three months, and 7.79% on an YTD basis. The stock is trading 7.41% and 20.33% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have an RSI of 64.00.
On January 20th, 2017, Amarin announced that it and its wholly owned subsidiary, Corsicanto II Designated Activity Company have entered into separate, privately negotiated purchase agreements with certain investors pursuant to which the Issuer will issue and sell $30.0 million in aggregate principal amount of 3.50% Exchangeable Senior Notes due 2047, which will be guaranteed by Amarin, at an issue price of 100%. Get free access to your research report on AMRN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All